Nerve conduction velocity in CMT1A: what else can we tell?

Fiore Manganelli, Chiara Pisciotta, Mary Reilly, Stefano Tozza, Angelo Schenone, G. M. Fabrizi, Tiziana Cavallaro, G. Vita, Luca Padua, F. Gemignani, M. Laurá, R. A C Hughes, Alessandra Solari, Davide Pareyson, Lucio Santoro, Maria Nolano, Maria Nolano, M. Grandis, I. Cabrini, Laura BertolasiA. Mazzeo, G. Majorana, F. Vitetta, V. Scaioli, Vidmer Scaioli, Claudia Ciano, Daniela Calabrese, J. Blake

Research output: Contribution to journalArticle

Abstract

Background and purpose: Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. Methods: Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot–Marie−Tooth Examination Score (CMTES). Results: NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. Conclusions: This is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.

Original languageEnglish
Pages (from-to)1566-1571
Number of pages6
JournalEuropean Journal of Neurology
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Neural Conduction
Action Potentials
Charcot-Marie-Tooth Disease
Ulnar Nerve
Peroneal Nerve
Median Nerve
Myelin Sheath
Italy
Ascorbic Acid
Lower Extremity

Keywords

  • Charcot−Marie−Tooth disease
  • CMT-TRIAAL/CMT-TRAUK
  • CMT1A
  • hereditary neuropathies
  • nerve conduction velocity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Manganelli, F., Pisciotta, C., Reilly, M., Tozza, S., Schenone, A., Fabrizi, G. M., ... Blake, J. (2016). Nerve conduction velocity in CMT1A: what else can we tell? European Journal of Neurology, 23(10), 1566-1571. https://doi.org/10.1111/ene.13079

Nerve conduction velocity in CMT1A : what else can we tell? / Manganelli, Fiore; Pisciotta, Chiara; Reilly, Mary; Tozza, Stefano; Schenone, Angelo; Fabrizi, G. M.; Cavallaro, Tiziana; Vita, G.; Padua, Luca; Gemignani, F.; Laurá, M.; Hughes, R. A C; Solari, Alessandra; Pareyson, Davide; Santoro, Lucio; Nolano, Maria; Nolano, Maria; Grandis, M.; Cabrini, I.; Bertolasi, Laura; Mazzeo, A.; Majorana, G.; Vitetta, F.; Scaioli, V.; Scaioli, Vidmer; Ciano, Claudia; Calabrese, Daniela; Blake, J.

In: European Journal of Neurology, Vol. 23, No. 10, 01.10.2016, p. 1566-1571.

Research output: Contribution to journalArticle

Manganelli, F, Pisciotta, C, Reilly, M, Tozza, S, Schenone, A, Fabrizi, GM, Cavallaro, T, Vita, G, Padua, L, Gemignani, F, Laurá, M, Hughes, RAC, Solari, A, Pareyson, D, Santoro, L, Nolano, M, Nolano, M, Grandis, M, Cabrini, I, Bertolasi, L, Mazzeo, A, Majorana, G, Vitetta, F, Scaioli, V, Scaioli, V, Ciano, C, Calabrese, D & Blake, J 2016, 'Nerve conduction velocity in CMT1A: what else can we tell?', European Journal of Neurology, vol. 23, no. 10, pp. 1566-1571. https://doi.org/10.1111/ene.13079
Manganelli F, Pisciotta C, Reilly M, Tozza S, Schenone A, Fabrizi GM et al. Nerve conduction velocity in CMT1A: what else can we tell? European Journal of Neurology. 2016 Oct 1;23(10):1566-1571. https://doi.org/10.1111/ene.13079
Manganelli, Fiore ; Pisciotta, Chiara ; Reilly, Mary ; Tozza, Stefano ; Schenone, Angelo ; Fabrizi, G. M. ; Cavallaro, Tiziana ; Vita, G. ; Padua, Luca ; Gemignani, F. ; Laurá, M. ; Hughes, R. A C ; Solari, Alessandra ; Pareyson, Davide ; Santoro, Lucio ; Nolano, Maria ; Nolano, Maria ; Grandis, M. ; Cabrini, I. ; Bertolasi, Laura ; Mazzeo, A. ; Majorana, G. ; Vitetta, F. ; Scaioli, V. ; Scaioli, Vidmer ; Ciano, Claudia ; Calabrese, Daniela ; Blake, J. / Nerve conduction velocity in CMT1A : what else can we tell?. In: European Journal of Neurology. 2016 ; Vol. 23, No. 10. pp. 1566-1571.
@article{86fba2a818d04628bc2defca3e6bbbb8,
title = "Nerve conduction velocity in CMT1A: what else can we tell?",
abstract = "Background and purpose: Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. Methods: Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot–Marie−Tooth Examination Score (CMTES). Results: NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. Conclusions: This is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.",
keywords = "Charcot−Marie−Tooth disease, CMT-TRIAAL/CMT-TRAUK, CMT1A, hereditary neuropathies, nerve conduction velocity",
author = "Fiore Manganelli and Chiara Pisciotta and Mary Reilly and Stefano Tozza and Angelo Schenone and Fabrizi, {G. M.} and Tiziana Cavallaro and G. Vita and Luca Padua and F. Gemignani and M. Laur{\'a} and Hughes, {R. A C} and Alessandra Solari and Davide Pareyson and Lucio Santoro and Maria Nolano and Maria Nolano and M. Grandis and I. Cabrini and Laura Bertolasi and A. Mazzeo and G. Majorana and F. Vitetta and V. Scaioli and Vidmer Scaioli and Claudia Ciano and Daniela Calabrese and J. Blake",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/ene.13079",
language = "English",
volume = "23",
pages = "1566--1571",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "10",

}

TY - JOUR

T1 - Nerve conduction velocity in CMT1A

T2 - what else can we tell?

AU - Manganelli, Fiore

AU - Pisciotta, Chiara

AU - Reilly, Mary

AU - Tozza, Stefano

AU - Schenone, Angelo

AU - Fabrizi, G. M.

AU - Cavallaro, Tiziana

AU - Vita, G.

AU - Padua, Luca

AU - Gemignani, F.

AU - Laurá, M.

AU - Hughes, R. A C

AU - Solari, Alessandra

AU - Pareyson, Davide

AU - Santoro, Lucio

AU - Nolano, Maria

AU - Nolano, Maria

AU - Grandis, M.

AU - Cabrini, I.

AU - Bertolasi, Laura

AU - Mazzeo, A.

AU - Majorana, G.

AU - Vitetta, F.

AU - Scaioli, V.

AU - Scaioli, Vidmer

AU - Ciano, Claudia

AU - Calabrese, Daniela

AU - Blake, J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background and purpose: Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. Methods: Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot–Marie−Tooth Examination Score (CMTES). Results: NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. Conclusions: This is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.

AB - Background and purpose: Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. Methods: Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot–Marie−Tooth Examination Score (CMTES). Results: NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. Conclusions: This is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.

KW - Charcot−Marie−Tooth disease

KW - CMT-TRIAAL/CMT-TRAUK

KW - CMT1A

KW - hereditary neuropathies

KW - nerve conduction velocity

UR - http://www.scopus.com/inward/record.url?scp=84987752669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987752669&partnerID=8YFLogxK

U2 - 10.1111/ene.13079

DO - 10.1111/ene.13079

M3 - Article

VL - 23

SP - 1566

EP - 1571

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 10

ER -